Technical Analysis for ABVX - ABIVAX Société Anonyme
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 10.49 | -1.04% | -0.11 |
ABVX closed down 1.04 percent on Wednesday, October 30, 2024, on 14 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Nov 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Weak + Overbought | Other | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.04% | |
Weak + Overbought | Other | -1.04% | |
Overbought Stochastic | Strength | -1.04% | |
Stochastic Reached Overbought | Strength | -1.87% | |
Weak + Overbought | Other | -1.87% | |
Outside Day | Range Expansion | -1.87% | |
Overbought Stochastic | Strength | -1.87% | |
Stochastic Sell Signal | Bearish | 1.84% |
Alert | Time |
---|---|
Possible Inside Day | about 13 hours ago |
Down 1% | about 18 hours ago |
Up 1% | about 18 hours ago |
60 Minute Opening Range Breakdown | 1 day ago |
Down 2 % | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Gastroenterology Colitis Diarrhea
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Gastroenterology Colitis Diarrhea
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.02 |
52 Week Low | 8.75 |
Average Volume | 122,583 |
200-Day Moving Average | 12.82 |
50-Day Moving Average | 11.01 |
20-Day Moving Average | 10.01 |
10-Day Moving Average | 10.46 |
Average True Range | 0.47 |
RSI (14) | 50.25 |
ADX | 20.1 |
+DI | 24.52 |
-DI | 17.18 |
Chandelier Exit (Long, 3 ATRs) | 9.95 |
Chandelier Exit (Short, 3 ATRs) | 10.17 |
Upper Bollinger Bands | 11.08 |
Lower Bollinger Band | 8.95 |
Percent B (%b) | 0.72 |
BandWidth | 21.29 |
MACD Line | -0.09 |
MACD Signal Line | -0.22 |
MACD Histogram | 0.131 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.96 | ||||
Resistance 3 (R3) | 10.99 | 10.87 | 10.88 | ||
Resistance 2 (R2) | 10.87 | 10.75 | 10.85 | 10.85 | |
Resistance 1 (R1) | 10.68 | 10.68 | 10.65 | 10.65 | 10.83 |
Pivot Point | 10.56 | 10.56 | 10.54 | 10.54 | 10.56 |
Support 1 (S1) | 10.37 | 10.44 | 10.34 | 10.34 | 10.15 |
Support 2 (S2) | 10.25 | 10.37 | 10.23 | 10.13 | |
Support 3 (S3) | 10.06 | 10.25 | 10.10 | ||
Support 4 (S4) | 10.03 |